Blood disorders
Haemophilia A
血友病 A
An inherited bleeding disorder caused by a deficiency of clotting factor VIII.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 132
- cities
- 52
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 11% of the world's English-language research papers on haemophilia A, 2021–2025 (7% in 2016–2020), and 13% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
132 hospitals in 52 cities
Order: papers led on haemophilia A, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 1 papers or 1 trial on haemophilia A, or was a site in 1 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens haemophilia A in that city. 42 more cities are in the menu below.
- 33 papers ledNo open trial led
- 25 papers led
- 24 papers ledNo open trial led
- 17 papers ledNo open trial led
- 9 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 31
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 43 papers led3 hospitals
- 35 papers led3 hospitals
- 9 papers led2 hospitals
- 8 papers led3 hospitals
- 7 papers led2 hospitals
- 6 papers led1 hospital
- 6 papers led2 hospitals
- 6 papers led2 hospitals
- 6 papers led3 hospitals
- 5 papers led2 hospitals
- 5 papers led2 hospitals
- 4 papers led1 hospital
- 4 papers led2 hospitals
- 4 papers led1 hospital
- 3 papers led2 hospitals
- 3 papers led2 hospitals
- 3 papers led1 hospital
- 3 papers led0 hospitals
- 2 papers led2 hospitals
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 2 papers led2 hospitals
- 2 papers led2 hospitals
- 1 paper led1 hospital
- 1 paper led0 hospitals
- 1 paper led1 hospital
- 0 papers led0 hospitals
open trials on haemophilia A in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 13 Nov 2026, with at least one listed hospital as lead sponsor or site, and at least one listed hospital's site marked open. 6 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07416526
Age 12 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07416604
Age 12 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Tianjin
- RecruitingSafety of KN057 Prophylaxis in Patients With Haemophilia A or B
- Phase
- Phase 3
- Started
- 2026-03
- Registry
- NCT07545395
Age 12 years to 65 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingTo Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06833983
Age 18 years to 65 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou
- RecruitingEvaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- Phase
- Phase 2/Phase 3
- Started
- 2024-01
- Registry
- NCT06111638
Age 18 years to Not stated; men only (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingSafety and Efficacy Study of NGGT003 in Hemophilia A Patients
- Phase
- Early phase 1
- Started
- 2024-01
- Registry
- NCT06238908
Age 18 years to Not stated; men only (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingLongitudinal Cohort of Thrombosis and Hemostasis Diseases
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06727669
Age not stated (registered criteria)
Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou
- RecruitingEfficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
- Phase
- Phase 3
- Started
- 2024-04
- Registry
- NCT07437404
Age Not stated to 6 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAn Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Registry
- NCT07644832
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Hefei, Jinan, Lanzhou, Taiyuan, Xi'an, Zhengzhou
- RecruitingITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
- Phase
- Phase 4
- Started
- 2023-11
- Registry
- NCT05888870
Age 14 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study of FVIII Gene Therapy for Hemophilia A
- Phase
- Early phase 1
- Started
- 2022-07
- Registry
- NCT05454774
Age 18 years to Not stated; men only (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Phase
- Phase 3
- Started
- 2022-12
- Registry
- NCT05611801
Age 1 year to 17 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan
- RecruitingGene Therapy for Chinese Hemophilia A
- Phase
- N/A
- Started
- 2021-03
- Registry
- NCT04728841
Age 18 years to Not stated; men only (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingOpen-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Phase
- Phase 3
- Started
- 2021-11
- Registry
- NCT05145127
Age 1 year to 74 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan
- RecruitingNational Longitudinal Cohort of Hematological Diseases
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT04645199
Age not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
Where these numbers come from
Papers
272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 13 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.